Propranolol with pembrolizumab and chemotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is newly diagnosed and cannot be removed by surgery or has spread, and you have not had standard cancer drugs for it (with limited exceptions).
- Your general condition is good (ECOG performance status 0 to 1).
- You can provide tumor tissue from a biopsy done within the last year, or you agree to a new biopsy before treatment starts.
- Your lab tests meet minimum safety levels (blood counts, kidney function, and liver/bilirubin levels).
- You can take propranolol by mouth (or by liquid through a feeding tube if swallowing is hard).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial studies whether adding propranolol (a common blood-pressure/heart medication) to standard chemotherapy and radiation can improve outcomes for people with esophageal adenocarcinoma. You would start propranolol around the time of treatment, with careful heart monitoring and study follow-up.
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
This trial tests whether adding a blood-pressure medicine (propranolol) to a combination of two immunotherapy drugs plus chemotherapy is safe and works better for locally advanced colon cancer that has not spread. It's for tumors that are pMMR/MSS, which are less likely to respond to immunotherapy alone, so the propranolol may help the immune system fight the cancer.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Hear when a new Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.